Long-Acting Cabotegravir And Rilpivirine Dosed Every Eight Weeks Effective, Well Tolerated In HIV-1, Data Show

Healio (1/25, Stulpin) reports “long-acting cabotegravir and rilpivirine dosed every 8 weeks was effective and well tolerated” for “the maintenance of HIV-1 virologic suppression,” demonstrating “noninferiority to the standard 4-week dosing at 152 weeks,...